CLL Cytogenetics 2 (Karyotyping + FISH for del17p + del 11q (ATM deletion) + trisomy 12)

Chromosomal analysis is important as it can provide information on the genetic makeup of the CLL cells. This information can guide treatment decisions and provide insights into the likely course of the disease.

This test provides detailed information about the presence or absence of specific chromosomal abnormalities in CLL cells, which are del17p, del 11q, and trisomy 12.

There is no specific preparation required. However, it’s recommended to inform your doctor of any medications you are currently taking.

Normal values indicate the absence of the chromosomal abnormalities. Presence of del17p, del 11q, or trisomy 12 is considered abnormal.

If the test results are abnormal, consult a hematologist or an oncologist who specializes in blood cancers.

The presence of del17p or del 11q indicates resistance to certain chemotherapy drugs, and alternative treatments like targeted therapies might be considered. Trisomy 12 requires careful monitoring and may involve different treatment approaches based on additional factors.

This test is usually performed at the time of CLL diagnosis. It may be repeated if there is a significant change in the disease or if considering a new treatment option.

No, chromosomal abnormalities are genetic in nature and are not influenced by lifestyle or environmental factors.

Currently, CLL is not curable, but it can be managed effectively with treatment. Newer therapies are continually being developed.

Managing CLL involves regular monitoring, following your doctor’s recommendations for treatment, and maintaining a healthy lifestyle.

If chromosomal abnormalities are detected, your doctor will discuss the implications regarding your CLL prognosis and treatment options.

FISH uses fluorescent probes to detect specific DNA sequences, allowing for the identification of chromosomal abnormalities, even when they might not be visible through conventional karyotyping.

Understanding the genetic makeup of Chronic Lymphocytic Leukemia cells is crucial for optimizing patient management strategies. The CLL Cytogenetics 2 test, combining Karyotyping and FISH, provides essential insights into the chromosomal abnormalities present. This information, combined with the expertise of your hematologist or oncologist, guides the development of a personalized treatment plan tailored to the genetic characteristics of your CLL. Regular monitoring and adherence to the treatment plan are vital components in the effective management of CLL.